New Publication in Small
In the study, a new generation of lipid nanoparticles (LNPs) was developed in collaboration with French partners, addressing the weaknesses of classical LNPs.
Schematic of biodegradable lipid nanoparticles for mRNA, pDNA and CRISPR delivery with organ targeting after IM and IV injection.
Published:
In the study, a new generation of lipid nanoparticles (LNPs) was developed in collaboration with French partners, addressing the weaknesses of classical LNPs. The so-called "Blue Lipid Nanoparticles" (BLNPs) are manufactured without organic solvents based on an aqueous process and without cholesterol. In addition, polyethylene glycol (PEG) was replaced with an alternative polymer (polyoxazoline) to avoid immune effects. They are suitable for transporting various genetic materials, including components of the CRISPR-Cas9 gene-editing system, and in mouse models they show expression primarily outside the liver, such as in the spleen.
Authors: Michael Streiber, Na Liu, Laurianne Simon, Franziska Adermann, Vivien Bachmann, Lucas Gath, Stephanie Hoeppener, Stephanie Schubert, Oliver Werz, Vincent Lapinte, Marie Morille, Michael Bauer, Adrian T. Press, Ulrich S. Schubert, Anja Traeger
The full article can be found here: https://doi.org/10.1002/smll.202511489External link